Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.980
-0.080 (-3.88%)
Apr 29, 2026, 12:47 PM EDT - Market open
Acurx Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 7.56 | 3.71 | 7.47 | 9.11 | 12.96 | |
| Cash & Short-Term Investments | 7.56 | 3.71 | 7.47 | 9.11 | 12.96 | |
| Cash Growth | 103.85% | -50.41% | -17.97% | -29.69% | 308.10% | |
| Other Receivables | 0.05 | 0.05 | 0.13 | - | - | |
| Receivables | 0.05 | 0.05 | 0.13 | - | - | |
| Prepaid Expenses | 0.09 | 0.1 | 0.11 | 0.26 | 0.3 | |
| Total Current Assets | 7.69 | 3.86 | 7.71 | 9.38 | 13.25 | |
| Accounts Payable | 0.01 | 0 | 0 | 0.03 | 0.06 | |
| Accrued Expenses | 2.41 | 3.24 | 3.04 | 2.03 | 0.78 | |
| Total Current Liabilities | 2.42 | 3.24 | 3.04 | 2.06 | 0.84 | |
| Common Stock | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Additional Paid-In Capital | 80.55 | 67.94 | 57.87 | 45.94 | 38.95 | |
| Retained Earnings | -75.29 | -67.32 | -53.22 | -38.64 | -26.55 | |
| Total Liabilities & Equity | 7.69 | 3.86 | 7.71 | 9.38 | 13.25 | |
| Net Cash (Debt) | 7.56 | 3.71 | 7.47 | 9.11 | 12.96 | |
| Net Cash Growth | 103.85% | -50.41% | -17.97% | -29.69% | 316.83% | |
| Net Cash Per Share | 5.04 | 4.59 | 11.80 | 16.85 | 30.36 | |
| Filing Date Shares Outstanding | 2.86 | 1.1 | 0.79 | 0.58 | 0.51 | |
| Total Common Shares Outstanding | 2.35 | 0.85 | 0.72 | 0.58 | 0.51 | |
| Working Capital | 5.27 | 0.62 | 4.67 | 7.32 | 12.41 | |
| Book Value Per Share | 2.24 | 0.72 | 6.45 | 12.58 | 24.30 | |
| Tangible Book Value | 5.27 | 0.62 | 4.67 | 7.32 | 12.41 | |
| Tangible Book Value Per Share | 2.24 | 0.72 | 6.45 | 12.58 | 24.30 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.